Subcutaneous Implants of a Cholesterol-Triglyceride-Buprenorphine Suspension in Rats
Table 2
(a) Rat plasma concentrations of buprenorphine with single dose of lipid-buprenorphine suspension. (b) Pharmacokinetics of lipid-bound buprenorphine in male and female rats.
(a)
Dose (/sex)
0 Hrs
6 hrs (day 0)
24 hrs (day 1)
48 hrs (day 2)
72 hrs (day 3)
96 hrs (day 4)
168 hrs (day 7)
216 hrs (day 9)
0.65 mg/kg
♂
0
1.9 ± 1.2
3.4 ± 0.8
1.9 ± 1.2
0.6 ± 0.2
0.4 ± 0.1
0
0
♀
0
1.2 ± 0.3
1.8 ± 0.8
1.2 ± 0.3
0.7 ± 0.1
0.3 ± 0
2.3 ± 3
0
1.35 mg/kg
♂
0
1.9 ± 0.8
5.4 ± 2.1
6.6 ± 2.4
5.1 ± 2.1
3.5 ± 1.2
No test
No test
♀
0
4.9 ± 3.0
9.6 ± 3.3
7.0 ± 1.5
7.4 ± 5.3
1.6 ± 0.6
Asterisk signifies clinically significant drug concentrations, defined as greater than 0.75 ng/mL of plasma buprenorphine.
